Total SvH 12m progression is 1.3 points higher in the triple positive group compared to the CCP group alone (p=0.016) (Table 2 + Fig 2) . Total SvH progression is also higher when comparing the triple positive to the negative group (p=0.046).
Conclusions: RA patients with antibodies to citrullinated peptides only have lower baseline erosions and less radiographic progression over 12m compared to those with a wider autoantibody repertoire. Baseline differences in erosion suggest that these antibodies may be pathogenic during the pre-RA disease process. Radiographic progression increases with autoantibody repertoire suggesting ongoing immune activation. Background: Stress and depression are common in patients with inflammatory polyarthritis (IP). There is little research on long term patterns of depression and stress or how these variables relate to disease activity, disability and pain. Objectives: To describe the natural history of stress and depression over five years and to assess the association of baseline, one year prior and current disease activity, disability and pain with longitudinal stress and depression. Methods: Patients recruited to the Norfolk Arthritis Register (NOAR) (inclusion criteria: ≥2 swollen joints for ≥4 weeks) from [2005] [2006] [2007] [2008] were included in this analysis. Demographics, medication use, 51 swollen/tender joint counts (SJC51/TJC51), pain visual analogue scale, HAQ, comorbidities and the Arthritis Impact Measurement Scales 2 (AIMS2) depression and stress subscales (range 0-10; high score = worse health status) were collected at baseline and years 1, 2, 3 and 5. Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP2) and C-reactive protein (CRP) were measured in baseline blood samples. ACR/EULAR 2010 RA criteria were applied to baseline characteristics. Depression and stress over five years were described using descriptive statistics. Multivariate random effects models were applied to assess the association of baseline disease activity (SJC51/TJC51), pain and disability with depression and stress over time adjusting for baseline age, gender, RF, anti-CCP2, CRP, sDMARD use, comorbidities, depression and stress. Similar methods were used to assess one year prior and current disease activity, pain and disability's association with stress and depression. Missing data were imputed using multiple imputation. Results: 509 patients were included (median (IQR) age: 57 (45, 68) years; 321 (63.1%) female; 305 (59.9%) ACR/EULAR RA). Baseline median (IQR) depression and stress were 2.5 (1.5, 4.5) and 4.0 (2.5, 5.5) respectively and remained constant over five years. Baseline SJC51, TJC51, pain and HAQ were not independently associated with depression or stress over five years. Current HAQ and pain, but not SJC51/TJC51, were independently associated with depression and stress (per unit increase in HAQ: depression β 0.83, 95% CI 0.69, 0.97; stress β 0.76, 95% CI 0.61, 0.90; per 1cm increase in pain: depression β 0.09, 95% CI 0.06, 0.12; stress β 0.09, 95% CI 0.05, 0.12). Higher HAQ was independently associated with increased depression and stress one assessment later (per unit increase in HAQ: depression β 0.21, 95% CI 0.09, 0.32; stress β 0.21, 95% CI 0.10, 0.33) but not pain, SJC51 or TJC51. Conclusions: There were no associations between measures of disease activity and depression or stress. Prospectively higher HAQ scores were associated with worse psychological health a year later. This may have implications for holistic management of IP. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.3432 
